This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q4 Potential of Becton Dickinson (BDX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 2.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk
by Zacks Equity Research
Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.
Top Stock Reports for Apple, Amgen & Becton, Dickinson
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes
by Zacks Equity Research
BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.
AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.
DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.42% and 1%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BD (BDX) This Earnings Season?
by Zacks Equity Research
BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AmerisourceBergen (ABC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 3.18% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP
by Debanjana Dey
MedTech companies' Q2 results are likely to reflect strength in customer demand. Let's see how ECL, NVRO and INSP are placed ahead of their earnings releases.
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.
Labcorp (LH) Q2 Earnings Lag Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of -1.44% and 1.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.